research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
Search
for
Sort by
Research
930-960 / 1000+ results
research Brigham Eyebrow Tool for Alopecia: A Reliable Assessment of Eyebrow Alopecia Areata
The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.
research Testosterone-stimulated weanlings as an alternative to castrated male rats in the Hershberger anti-androgen assay
Using testosterone-stimulated weanling rats can effectively replace castrated rats for anti-androgen testing, reducing animal stress.
research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
research The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research STRIAA (Severity TRichoscopy Index Alopecia Areata): Validation of a Novel Trichoscopic Tool for Evaluation of Alopecia Areata
The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.
research A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata
Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Comparative analysis of temperature‐controlled cryotherapy versus intralesional triamcinolone acetonide injection for alopecia areata: An intrasubject split‐lesion pilot study
Cryotherapy with precise temperature control is a promising treatment for alopecia areata.
research Alopecia areata clinical trial enrollment and retention outcome factors among underrepresented ethnic and racial groups: A cross-sectional study
Clinical trials for alopecia areata need better inclusion and retention of patients of color.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research An Uncontrolled Innovative Test of Cryo-Chilled Carbon Dioxide as A Novel Amplification of a Nano-Botanical Multi-Acting Therapy in Advanced Stage Androgenetic Alopecia (Aga)
The treatment showed promising hair regrowth in advanced-stage hair loss.
research 40753 Trends in ethnoracial representation in alopecia areata clinical trials: a cross-sectional study
Hispanic and Black patients are underrepresented in alopecia areata clinical trials.
research BH23 Mind the gap! Navigating barriers to care access for patients with alopecia areata in the UK: a qualitative interview study
Patients with alopecia areata in the UK face barriers to care, needing better-defined pathways and more education for general practitioners.
research MP-09.08
The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
research SAT-288 Successful Virilization of a PAIS Patient with a Missense Mutation In The Ligand-binding Domain Of The Androgen Receptor with Combined High-dose Testosterone and Aromatase Inhibitor
A 12-year-old boy with PAIS successfully developed male characteristics using high-dose testosterone and anastrozole.
research A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
MK-5108 is safe and shows potential against tumors, especially alone.
research Educating for Empathy: Impact of a Targeted Alopecia Areata Curriculum on Middle School Students
The program improved students' understanding and acceptance of alopecia areata.
research 586 Increase in CD8+ effector memory cells re-expressing CD45RA (TEMRA) reflects disease activity and enables early prediction of therapeutic outcome in rapidly progressive alopecia areata
Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
research Forging the Future: 2018 Alopecia Areata Research Summit Summary Report
The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
research Translation, cultural adaptation and validation of the Brazilian version of the Alopecia Areata Quality of Life Index (AA-QLI-BRA)
The Brazilian version of the Alopecia Areata Quality of Life Index is reliable for assessing patients' quality of life.
research Blinding in Placebo-Controlled Trials
The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.
research Safety and biopsy outcomes of a topical treatment (SM04554) for male androgenetic alopecia (AGA): Results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial
Topical treatment SM04554 safely promotes hair growth in male baldness.
research This Week in JAMA
Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.